



A Pfizer Company

SAFETY DATA SHEET

Revision date: 07-Nov-2018

Version: 1.0

Page 1 of 10

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Diltiazem Hydrochloride Injection (Hospira, Inc.)

Trade Name: Not established

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used for angina high blood pressure (hypertension)

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 1B

Label Elements

Signal Word: Danger

Hazard Statements: H360D - May damage the unborn child

Precautionary Statements:

P202 - Do not handle until all safety precautions have been read and understood

P281 - Use personal protective equipment as required

P308 + P313 - IF exposed or concerned: Get medical attention/advice

P405 - Store locked up

P501 - Dispose of contents/container in accordance with all local and national regulations



SAFETY DATA SHEET

Material Name: Diltiazem Hydrochloride Injection (Hospira, Inc.)

Page 2 of 10

Revision date: 07-Nov-2018

Version: 1.0

Other Hazards An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Diltiazem Hydrochloride	33286-22-5	251-443-3	Acute Tox.4 (H302) Repr.1B (H360D)	0.5
SODIUM HYDROXIDE	1310-73-2	215-185-5	Skin Corr. 1A (H314)	**
HYDROCHLORIC ACID	7647-01-0	231-595-7	Skin Corr.1B (H314) STOT SE 3 (H335)	**

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Water for Injection	7732-18-5	231-791-2	Not Listed	*
Sodium citrate, dihydrate	6132-04-3	Not Listed	Not Listed	*
Citric acid, anhydrous	77-92-9	201-069-1	Not Listed	*
Sorbitol	6706-59-8	Not Listed	Not Listed	*

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.

Skin Contact: Remove clothing and wash affected skin with soap and water. If irritation occurs or persists, get medical attention.

Ingestion: Get medical attention. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.

Inhalation: Remove to fresh air. If not breathing, give artificial respiration. Get medical attention.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: No data available

SAFETY DATA SHEET

Material Name: Diltiazem Hydrochloride Injection (Hospira, Inc.)

Page 3 of 10

Revision date: 07-Nov-2018

Version: 1.0

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed
Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of the spill if it is safe to do so. Collect wash with a noncombustible absorbent material and transfer to labeled container for treatment and disposal.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Diltiazem Hydrochloride
Pfizer OEL TWA-8 Hr:

70µg/m³

SAFETY DATA SHEET

Material Name: Diltiazem Hydrochloride Injection (Hospira, Inc.)

Page 4 of 10

Revision date: 07-Nov-2018

Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

SODIUM HYDROXIDE

ACGIH Ceiling Threshold Limit:	2 mg/m ³
Australia PEAK	2 mg/m ³
Austria OEL - MAKs	2 mg/m ³
Bulgaria OEL - TWA	2.0 mg/m ³
Czech Republic OEL - TWA	1 mg/m ³
Estonia OEL - TWA	1 mg/m ³
France OEL - TWA	2 mg/m ³
Greece OEL - TWA	2 mg/m ³
Hungary OEL - TWA	2 mg/m ³
Japan - OELs - Ceilings	2 mg/m ³
Latvia OEL - TWA	0.5 mg/m ³
OSHA - Final PELs - TWAs:	2 mg/m ³
Poland OEL - TWA	0.5 mg/m ³
Slovakia OEL - TWA	2 mg/m ³
Slovenia OEL - TWA	2 mg/m ³
Sweden OEL - TWAs	1 mg/m ³
Switzerland OEL - TWAs	2 mg/m ³

HYDROCHLORIC ACID

ACGIH Ceiling Threshold Limit:	2 ppm
Australia PEAK	5 ppm
	7.5 mg/m ³
Austria OEL - MAKs	5 ppm
	8 mg/m ³
Belgium OEL - TWA	5 ppm
	8 mg/m ³
Bulgaria OEL - TWA	5 ppm
	8.0 mg/m ³
Cyprus OEL - TWA	5 ppm
	8 mg/m ³
Czech Republic OEL - TWA	8 mg/m ³
Estonia OEL - TWA	5 ppm
	8 mg/m ³
Germany - TRGS 900 - TWAs	2 ppm
	3 mg/m ³
Germany (DFG) - MAK	2 ppm
	3.0 mg/m ³
Greece OEL - TWA	5 ppm
	7 mg/m ³
Hungary OEL - TWA	8 mg/m ³
Ireland OEL - TWAs	5 ppm
	8 mg/m ³
Italy OEL - TWA	5 ppm
	8 mg/m ³
Japan - OELs - Ceilings	2 ppm
	3.0 mg/m ³
Latvia OEL - TWA	5 ppm
	8 mg/m ³
Lithuania OEL - TWA	5 ppm
	8 mg/m ³

SAFETY DATA SHEET

Material Name: Diltiazem Hydrochloride Injection (Hospira, Inc.)

Page 5 of 10

Revision date: 07-Nov-2018

Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Luxembourg OEL - TWA	5 ppm 8 mg/m ³
Malta OEL - TWA	5 ppm 8 mg/m ³
Netherlands OEL - TWA	8 mg/m ³
Poland OEL - TWA	5 mg/m ³
Portugal OEL - TWA	5 ppm 8 mg/m ³
Romania OEL - TWA	5 ppm 8 mg/m ³
Slovakia OEL - TWA	5 ppm 8.0 mg/m ³
Slovenia OEL - TWA	5 ppm 8 mg/m ³
Spain OEL - TWA	5 ppm 7.6 mg/m ³
Switzerland OEL -TWAs	2 ppm 3.0 mg/m ³
Vietnam OEL - TWAs	5 mg/m ³

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands:

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes:

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection:

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Liquid	Color:	No data available.
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture
Solvent Solubility:	No data available		
Water Solubility:	No data available		
pH:	No data available.		

SAFETY DATA SHEET

Material Name: Diltiazem Hydrochloride Injection (Hospira, Inc.)

Page 6 of 10

Revision date: 07-Nov-2018

Version: 1.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)
Diltiazem Hydrochloride
No data available
Water for Injection
No data available
Citric acid, anhydrous
No data available
Sodium citrate, dihydrate
No data available
SODIUM HYDROXIDE
No data available
HYDROCHLORIC ACID
No data available
Sorbitol
No data available
Decomposition Temperature (°C): No data available.
Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C):	No data available
Flammability (Solids):	No data available
Flash Point (Liquid) (°C):	No data available
Upper Explosive Limits (Liquid) (% by Vol.):	No data available
Lower Explosive Limits (Liquid) (% by Vol.):	No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Short Term: May cause eye irritation (based on components) Drugs of this class have been associated with rare, but potentially serious cardiac events. These events have not been observed from occupational exposures, however, those with preexisting cardiovascular illnesses may be at increased risk from exposure.

Long Term: Animal studies indicate that this material may cause adverse effects on the fetus

SAFETY DATA SHEET

Material Name: Diltiazem Hydrochloride Injection (Hospira, Inc.)

Page 7 of 10

Revision date: 07-Nov-2018

Version: 1.0

11. TOXICOLOGICAL INFORMATION

Known Clinical Effects: Ingestion of this material may cause effects similar to those seen in clinical use including dizziness, fatigue, hypotension (low blood pressure), edema and dyspnea.

Acute Toxicity: (Species, Route, End Point, Dose)

Diltiazem Hydrochloride

Rat	Oral	LD50	560 mg/kg
Rat	Para-periosteal	LD50	38mg/kg
Rat	Subcutaneous	LD50	520mg/kg
Mouse	Oral	LD50	508mg/kg
Mouse	Intravenous	LD50	58mg/kg

Citric acid, anhydrous

Rat	Oral	LD50	3000 mg/kg
-----	------	------	------------

HYDROCHLORIC ACID

Rat	Oral	LD 50	238-277 mg/kg
-----	------	-------	---------------

Irritation / Sensitization: (Study Type, Species, Severity)

Citric acid, anhydrous

Eye Irritation	Rabbit	Severe
Skin Irritation	Rabbit	Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Diltiazem Hydrochloride

1 Month(s)	Rat	Oral	100 mg/kg/day	NOAEL	Liver, Blood, Heart
1 Month(s)	Dog	Oral	5 mg/kg/day	NOAEL	Kidney, Heart
6 Month(s)	Dog	Oral	10 mg/kg/day	LOAEL	Heart, Liver, Cardiovascular system
1 Year(s)	Dog	Oral	5 mg/kg/day	LOAEL	Cardiovascular system, Heart

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Diltiazem Hydrochloride

Reproductive & Fertility	Rat	Oral	50 mg/kg/day	NOAEL	Fertility
Embryo / Fetal Development	Mouse	Oral	25 mg/kg/day	LOAEL	Embryotoxicity
Embryo / Fetal Development	Rat	Oral	100 mg/kg/day	NOAEL	Fetotoxicity
Embryo / Fetal Development	Rabbit	Intraperitoneal	6.3 mg/kg/day	LOAEL	Fetotoxicity, Teratogenic
Embryo / Fetal Development	Rabbit	Oral	17.5 mg/kg/day	NOAEL	Fetotoxicity, Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Diltiazem Hydrochloride

Bacterial Mutagenicity (Ames)	<i>Salmonella</i> , <i>E. coli</i>	Negative
<i>In Vivo</i> Mammalian Cell Mutagenicity		Negative
<i>In Vitro</i> Mammalian Cell Mutagenicity		Negative

HYDROCHLORIC ACID

SAFETY DATA SHEET

Material Name: Diltiazem Hydrochloride Injection (Hospira, Inc.)

Page 8 of 10

Revision date: 07-Nov-2018

Version: 1.0

11. TOXICOLOGICAL INFORMATION

Bacterial Mutagenicity (Ames) *Salmonella* Negative
In Vivo Micronucleus Rat Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Diltiazem Hydrochloride

21 Month(s) Mouse Oral 30 mg/kg/day NOAEL Not carcinogenic
24 Month(s) Rat Oral 100 mg/kg/day NOAEL Not carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

HYDROCHLORIC ACID

IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

SAFETY DATA SHEET

Material Name: Diltiazem Hydrochloride Injection (Hospira, Inc.)

Page 9 of 10

Revision date: 07-Nov-2018

Version: 1.0

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Diltiazem Hydrochloride

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	developmental toxicity 2/27/2001
Australia (AICS):	Present
EU EINECS/ELINCS List	251-443-3

SODIUM HYDROXIDE

CERCLA/SARA 313 Emission reporting	Not Listed
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	1000 lb
California Proposition 65	454 kg
Inventory - United States TSCA - Sect. 8(b)	Not Listed
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Present
EU EINECS/ELINCS List	Schedule 5
	Schedule 6
	215-185-5

HYDROCHLORIC ACID

CERCLA/SARA 313 Emission reporting	1.0 %
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	5000 lb
CERCLA/SARA - Section 302 Extremely Hazardous TPQs	2270 kg
CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs	500 lb
California Proposition 65	5000 lb
Inventory - United States TSCA - Sect. 8(b)	Not Listed
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Present
EU EINECS/ELINCS List	Schedule 5
	Schedule 6
	231-595-7

Water for Injection

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	Present
	231-791-2

Sodium citrate, dihydrate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present

SAFETY DATA SHEET

Material Name: Diltiazem Hydrochloride Injection (Hospira, Inc.)

Page 10 of 10

Revision date: 07-Nov-2018

Version: 1.0

15. REGULATORY INFORMATION

EU EINECS/ELINCS List	Not Listed
-----------------------	------------

Citric acid, anhydrous

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	201-069-1

Sorbitol

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
Reproductive toxicity-Cat.1B; H360D - May damage the unborn child
Skin corrosion/irritation-Cat.1A; Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage
Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation

Data Sources: Safety data sheets for individual ingredients. Pfizer proprietary drug development information.

Reasons for Revision: New data sheet.

Revision date: 07-Nov-2018
Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet